ArticleContemporary clinical trials2023
Design of a pragmatic clinical trial to improve screening and treatment for opioid use disorder in primary care.
Article in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Clinical Decision Support and Cardiometabolic Medication Adherence: A Randomized Clinical Trial.JAMA network open · 2025 · on this mapTrial
- A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians.Addiction science & clinical practice · 2023Trial
- Machine Learning Prediction and Reducing Overdoses With Electronic Health Record Nudges (mPROVEN) in the Primary Care Setting: Protocol for a Cluster Randomized Controlled Trial.JMIR research protocols · 2026Article
- Implementation of screening and assessment tools for diagnosing opioid use disorder: A systematic review.Drug and alcohol dependence reports · 2025Review
- Article
- Collaborative pharmacy research across integrated health systems: A purpose and promise for opportunities to study the complete medication-use process.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2025Article
- Randomized Pilot of a Clinical Decision Support Tool to Increase Suicide Screening for at-Risk Primary Care Patients With Opioid Use Disorder.AJPM focus · 2024Article
- Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings.BMC primary care · 2024Article
- Barriers and Facilitators to Using a Clinical Decision Support Tool for Opioid Use Disorder in Primary Care.Journal of the American Board of Family Medicine : JABFM · 2024Article
- The potential impact of clinical decision support on nonwaivered primary care clinicians' prescribing of buprenorphine.Health affairs scholar · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundOpioid-related deaths continue to rise in the U.S. A shared decision-making (SDM) system to help primary care clinicians (PCCs) identify and treat patients with opioid use disorder (OUD) could help address this crisis.
methodsIn this cluster-randomized trial, primary care clinics in three healthcare systems were randomized to receive or not receive access to an OUD-SDM system. The OUD-SDM system alerts PCCs and patients to elevated risk of OUD and supports OUD screening and treatment. It includes guidance on OUD screening and diagnosis, treatment selection, starting and maintaining patients on buprenorphine for waivered clinicians, and screening for common comorbid conditions. The primary study outcome is, of patients at high risk for OUD, the percentage receiving an OUD diagnosis within 30 days of index visit. Additional outcomes are, of patients at high risk for or with a diagnosis of OUD, (a) the percentage receiving a naloxone prescription, or (b) the percentage receiving a medication for OUD (MOUD) prescription or referral to specialty care within 30 days of an index visit, and (c) total days covered by a MOUD prescription within 90 days of an index visit.
resultsThe intervention started in April 2021 and continues through December 2023. PCCs and patients in 90 clinics are included; study results are expected in 2024.
conclusionThis protocol paper describes the design of a multi-site trial to help PCCs recognize and treat OUD. If effective, this OUD-SDM intervention could improve screening of at-risk patients and rates of OUD treatment for people with OUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.